A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with
locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane,
and capecitabine as prior therapy, and who are refractory to the last prior therapy for their
disease.